Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide and Tubuloglomerular Feedback in Type 1 Diabetes
NCT06981234Phase 2Recruiting
- Sponsor
- University of California, San Diego
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetazolamide in type 1 diabetes mellitus (T1D) (2 arms), sponsored by University of California, San Diego. Primary endpoints: Change in measured Glomerular Filtration Rate percent at 10 weeks, Preservation of Serum Bicarbonate at 10 weeks and 2 more. Started Aug 2024; status: recruiting.
02
Drugs
acetazolamide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06981234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981234.